Artivion's medical device franchise carries analyst consensus targets implying more than 73% upside from current levels and a risk/reward ratio of roughly 10-to-1 in favor of the bull case, but the near-term picture is complicated by a recent 35% earnings miss, free cash flow that is negative relative to net income, a confirmed price downtrend, and eight disclosed supplier concentration vulnerabilities including sole manufacturers for key product families.
Thesis pillars
- Large Consensus Implied Upside→Stable
- Above Peer Growth Profile→Stable
- Negative Free Cash Flow Risk→Stable
- +1 more pillar — see the Why tab for full reasoning
Artivion, Inc. (AORT) Stock Analysis
Recovery setup
Healthcare · Medical Devices
Wait for pullback to $23.90. Weak momentum; also below 200-day MA (death cross) — blocks BUY_NOW at $25.00. Engine's entry $23.90 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Supplier: Endospan (NEXUS family); Concentration risk — Supplier: AMDS sole manufacturer.
Artivion manufactures medical devices and processes implantable human tissues for cardiac and vascular surgery, with segments spanning Medical Devices (aortic stent grafts, On-X valves, BioGlue sealant) and Preservation Services. Products are sold globally across North America,... Read more
Wait for pullback to $23.90. Weak momentum; also below 200-day MA (death cross) — blocks BUY_NOW at $25.00. Engine's entry $23.90 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Supplier: Endospan (NEXUS family); Concentration risk — Supplier: AMDS sole manufacturer. Chart setup: Death cross but MACD improving, RSI 54. Mixed signals. Hold existing position. | News modifier +1 (HOLD_IF_HOLDING → STRONG_BUY_WAIT) Score 5.9/10, moderate confidence.
Passes 6/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.70, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.
Recent developments
updated 2026-07-26Recent Developments — Artivion, Inc.
Latest news
- NEWS What To Expect From Artivion’s (AORT) Q1 Earnings - StockStory — StockStory neutral
- NEWS What To Expect From Artivion’s (AORT) Q1 Earnings - FinancialContent — FinancialContent neutral
- NEWS Conestoga Capital Adds Artivion to Portfolio Amid Market Volatility - HarianBasis.co — HarianBasis.co positive
- NEWS Strong Catalysts Drive Artivion (AORT) - Insider Monkey — Insider Monkey positive
- NEWS Strong Catalysts Drive Artivion (AORT) - Yahoo Finance — Yahoo Finance positive
Generated 2026-07-26T08:02:04Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierEndospan (NEXUS family)10-K Item 1A: 'the NEXUS family of products are solely manufactured by Endospan in Herzliya, Israel'
- HIGHSupplierAMDS sole manufacturer10-K Item 1A: 'The AMDS product is solely manufactured by a supplier in Charlotte, North Carolina'
- HIGHSupplierBioGlue single-supplier delivery devices10-K Item 1A: 'We are significantly dependent on our revenues from BioGlue ... The delivery devices are manufactured by a single supplier, using resin supplied by a different single supplier'
- HIGHSupplierOn-X AAP single-supplier grafts10-K Item 1A: 'We purchase grafts for our On-X AAP from a single supplier'
- MEDIUMProductBioGlue10-K Item 1A: 'BioGlue is a significant source of our revenues'
- MEDIUMProductOn-X products10-K Item 1A: 'On-X products are a significant source of our revenues'
- MEDIUMProductaortic stent grafts10-K Item 1A: 'Aortic stent grafts are a significant source of our revenues'
- MEDIUMProducttissue preservation services10-K Item 1A: 'Tissue preservation services are a significant source of our revenues'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $23.90. Weak momentum; also below 200-day MA (death cross) — blocks BUY_NOW at $25.00. Engine's entry $23.90 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Supplier: Endospan (NEXUS family); Concentration risk — Supplier: AMDS sole manufacturer. Chart setup: Death cross but MACD improving, RSI 54. Mixed signals. Hold existing position. | News modifier +1 (HOLD_IF_HOLDING → STRONG_BUY_WAIT) Target $36.54 (+46.2%), stop $21.98 (−13.7%), A.R:R 3.0:1. Score 5.9/10, moderate confidence.
Take-profit target: $36.54 (+44.5% upside). Target $36.54 (+46.2%), stop $21.98 (−13.7%), A.R:R 3.0:1. Stop-loss: $21.98.
Concentration risk — Supplier: Endospan (NEXUS family); Concentration risk — Supplier: AMDS sole manufacturer; Below 200-MA, MA slope -7.2%/30d (confirmed downtrend).
Artivion, Inc. trades at a P/E of 101.1 (forward 35.1). TrendMatrix value score: 5.5/10. Verdict: Buy (Wait for Entry).
14 analysts cover AORT with a consensus score of 4.3/5. Average price target: $42.
What does Artivion, Inc. do?Artivion manufactures medical devices and processes implantable human tissues for cardiac and vascular surgery, with...
Artivion manufactures medical devices and processes implantable human tissues for cardiac and vascular surgery, with segments spanning Medical Devices (aortic stent grafts, On-X valves, BioGlue sealant) and Preservation Services. Products are sold globally across North America, EMEA, APAC, and LATAM from facilities in Georgia, Texas, and Germany. BioGlue, On-X products, aortic stent grafts, and tissue preservation services are each individually characterized as significant revenue sources.